Therefore, targeted delivery, structure-based design, precise modulation strategies, and combination therapies could help improve efficacy and minimize off-target effects, thereby unlocking IL-22’s therapeutic potential for treating MASLD/MASH. Here, IL22 is linked to metabolic dysfunction-associated steatohepatitis.